Quadrant Capital Group LLC Sells 556 Shares of Balchem Co. (NASDAQ:BCPC)

Quadrant Capital Group LLC cut its holdings in Balchem Co. (NASDAQ:BCPC) by 51.5% during the 4th quarter, Holdings Channel reports. The fund owned 523 shares of the basic materials company’s stock after selling 556 shares during the period. Quadrant Capital Group LLC’s holdings in Balchem were worth $78,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Signaturefd LLC lifted its position in shares of Balchem by 123.0% during the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after buying an additional 91 shares in the last quarter. Principal Securities Inc. bought a new stake in Balchem during the 4th quarter worth approximately $28,000. Operose Advisors LLC bought a new position in shares of Balchem in the third quarter worth approximately $31,000. GAMMA Investing LLC purchased a new stake in shares of Balchem in the fourth quarter worth $56,000. Finally, Allworth Financial LP raised its position in shares of Balchem by 17.8% during the 4th quarter. Allworth Financial LP now owns 953 shares of the basic materials company’s stock valued at $142,000 after purchasing an additional 144 shares during the period. Institutional investors own 87.91% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright increased their price target on Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research report on Friday, May 10th.

Balchem Trading Down 0.5 %

Balchem stock opened at $153.02 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.61 and a quick ratio of 1.72. The firm’s 50 day moving average price is $150.75 and its 200-day moving average price is $144.15. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $159.52. The stock has a market cap of $4.96 billion, a P/E ratio of 43.23, a PEG ratio of 3.63 and a beta of 0.72.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings results on Friday, May 3rd. The basic materials company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $239.66 million during the quarter, compared to analysts’ expectations of $234.12 million. Balchem had a return on equity of 11.03% and a net margin of 12.35%. On average, equities analysts predict that Balchem Co. will post 3.86 earnings per share for the current fiscal year.

Insider Activity at Balchem

In other Balchem news, CAO William A. Backus sold 7,000 shares of Balchem stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $155.19, for a total value of $1,086,330.00. Following the sale, the chief accounting officer now owns 5,914 shares of the company’s stock, valued at approximately $917,793.66. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Balchem news, CAO William A. Backus sold 7,000 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the completion of the transaction, the chief accounting officer now owns 5,914 shares in the company, valued at $917,793.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael Robert Sestrick sold 1,929 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $154.45, for a total transaction of $297,934.05. Following the completion of the sale, the senior vice president now owns 4,878 shares in the company, valued at $753,407.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,929 shares of company stock valued at $2,149,164. Insiders own 1.25% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.